The heart in Fabry's disease

Cardiovascular Pathology

Volumn 20, Issue 1, 2011, Pages 8-14

  Sheppard, Mary N ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Arrhythmias; Cardiac failure; Conduction abnormalities; Enzyme replacement therapy; Fabry's disease; Left ventricular hypertrophy; Sudden death; Valve abnormalities

Indexed keywords

ARTERY DISEASE; CARDIOMEGALY; CARDIOMYOPATHY; ENZYME REPLACEMENT; FABRY DISEASE; GENETIC VARIABILITY; HEART DISEASE; HEART FUNCTION; HEART INJURY; HEART VENTRICLE FUNCTION; HUMAN; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

ALPHA-GALACTOSIDASE; CARDIOMYOPATHIES; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; MALE; MYOCARDIUM; RECOMBINANT PROTEINS;

EID: 78650416558     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2009.10.003     Document Type: Review

References (59)

1. Adam T, Alexandrescu L, Voinea F, Toringhibel M, and Hancu A Fabry's disease Rom.J Intern Med 44 2006 455 464
2. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, and Osterziel KJ The heart in Anderson Fabry disease Z Kardiol 91 2002 786 795
3. Linthorst GE, Poorthuis BJ, and Hollak CE Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results J Am Coll Cardiol 51 2008 2082 2083
4. Applegarth DA, Toone JR, and Lowry RB Incidence of inborn errors of metabolism in British Columbia, 1969-1996 Pediatrics 105 2000 e10
5. Meikle PJ, Hopwood JJ, Clague AE, and Carey WF Prevalence of lysosomal storage disorders JAMA 281 1999 249 254
6. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, and Van Diggelen OP The frequency of lysosomal storage diseases in The Netherlands Hum Genet 105 1999 151 156
7. Mehta A, Ricci R, Widmer U, Dehout F, Garcia DL, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, and Beck M Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Eur J Clin Invest 34 2004 236 242
8. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, and Desnick RJ Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype Kidney Int 64 2003 801 807
9. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, and Sunder-Plassmann G Results of a nationwide screening for Anderson-Fabry disease among dialysis patients J Am Soc Nephrol 15 2004 1323 1329 (Pubitemid 38526014)
10. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, and Sakuraba H An atypical variant of Fabry's disease in men with left ventricular hypertrophy N Engl J Med 333 1995 288 293
11. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, and Elliott PM Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy Circulation 105 2002 1407 1411
12. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, and Frustaci A Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy Circulation 110 2004 1047 1053
13. Schirinzi A, Centra M, Prattichizzo C, Gigante M, De Fabritiis M, Giancaspro V, Petrarulo F, Santacroce R, Margaglione M, Gesualdo L, and Ranieri E Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent Probe Amplification (MLPA) Mol Genet Metab 94 2008 382 385
14. Yang CC, Lai LW, Whitehair O, Hwu WL, Chiang SC, and Lien YH Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease Clin Genet 63 2003 205 209
15. Ferrans VJ, Hibbs RG, and Burda CD The heart in Fabry's disease. A histochemical and electron microscopic study Am J Cardiol 24 1969 95 110
16. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, and Wilcox WR Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 138 2003 338 346
17. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, and Moller JH Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies Circulation 54 1976 818 825
18. Bass JL, Shrivastava S, Grabowski GA, Desnick RJ, and Moller JH The M-mode echocardiogram in Fabry's disease Am Heart J 100 1980 807 812
19. Elleder M Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases Acta Paediatr Suppl 92 2003 46 53
20. Palecek T, Lubanda JC, Magage S, Karetova D, Bultas J, and Linhart A Cardiac manifestation of Fabry's disease: current knowledge Vnitr.Lek. 50 2004 846 851
21. Rohard I, Schaefer E, Kampmann C, Beck M, and Gal A Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease J Inherit Metab Dis 122 2008 e132 e157
22. Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M, Wiethoff CM, Trubel H, and Beck M The right ventricle in Fabry disease Acta Paediatr Suppl 94 2005 15 18
23. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, and Beck M Cardiac manifestations of Anderson-Fabry disease in heterozygous females J Am Coll Cardiol 40 2002 1668 1674
24. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, and Desnick RJ An atypical variant of Fabry's disease with manifestations confined to the myocardium N Engl J Med 324 1991 395 399
25. Germain DP A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant Contrib Nephrol 136 2001 234 240
26. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J, Elleder M, and Aschermann M Cardiac manifestations in Fabry disease J Inherit Metab Dis 24 Suppl 2 2001 75 83
27. Teraguchi H, Takenaka T, Yoshida A, Taguchi S, Ninomiya K, Yoshida H, Horinouchi M, Yonezawa S, Nakao S, Minagoe S, and Tei S End-stage cardiac manifestations and autopsy findings in patients with cardiac Fabry disease J Cardiol 43 2004 98 99
28. Tanaka H, Adachi K, Yamashita Y, Toshima H, and Koga Y Four cases of Fabry's disease mimicking hypertrophic cardiomyopathy J Cardiol 18 1988 705 718
29. Orimo S, Iwasaki T, Yoshino H, Arai M, and Hiyamuta E An autopsied case of Fabry's disease presenting with parkinsonism and cardiomegaly as a cardinal clinical manifestation Rinsho Shinkeigaku 34 1994 1003 1007
30. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, and Dorazilova V Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy Virchows Arch A Pathol Anat Histopathol 417 1990 449 455
31. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, Tome MT, McKenna WJ, Lee P, and Camici PG Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A Heart 92 2006 357 360
32. Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG, Stienen GJ, Russo MA, Paulus WJ, Frustaci A, and van DV Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease Am J Pathol 172 2008 1482 1490
33. Moon JC, Sheppard MN, Reed E, Lee P, Elliott PM, and Pennell DJ The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease J Cardiovasc Magn Reson 8 2006 479 482
34. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, and Tei C Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study J Cardiol 51 2008 50 59
35. De CF, Esposito A, Belloni E, Pieroni M, Perseghin G, Chimenti C, Frustaci A, and Del MA Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy AJR Am J Roentgenol 192 2009 W97 102
36. Shah JS, Lee P, Hughes D, Thaman R, Sachdev B, Pellerin D, Mehta A, and Elliott PM The natural history of left ventricular systolic function in Anderson-Fabry disease Heart 91 2005 533 534 (Pubitemid 40432794)
37. Frustaci A, and Chimenti C Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue Circulation 116 2007 e350 e351
38. Sivaloganathan S Fabry's disease-a rare cause of sudden death Med Sci Law 32 1992 263 266
39. Carter N, Milroy CM, and Shepherd RT Sudden death in elderly women with Fabry's disease Am J Forensic Med Pathol 16 1995 21 26
40. Mignani R, and Cagnoli L Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications J Nephrol 17 2004 354 363
41. Schiffmann R, Ries M, Timmons M, Flaherty JT, and Brady RO Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting Nephrol Dial Transplant 21 2006 345 354
42. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, and Brady RO Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2001 2743 2749
43. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, and Desnick RJ Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy N Engl J Med 345 2001 25 32
44. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci M, Procaccini D, Lo SN, Federico S, and Cianciaruso B Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease Clin Genet 66 2004 158 165
45. Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, Pasquali S, Savoldi S, Comotti C, and Cianciaruso B Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement Am J Kidney Dis 46 2005 120 127
46. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, and Strotmann JM Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study Circulation 108 2003 1299 1301
47. Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, Moneti G, and Cagnoli L Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study Kidney Int 65 2004 1381 1385
48. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, and Beck M Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study J Inherit Metab Dis 26 2003 617 627
49. Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, Perlee LT, Quezado M, Spollen LE, Wustman BA, and Schiffmann R Cellular and tissue localization of globotriaosylceramide in Fabry disease Virchows Arch 451 2007 823 834
50. Clarke JT, and Iwanochko RM Enzyme replacement therapy of Fabry disease Mol Neurobiol 32 2005 43 50
51. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J, Lee P, Elliott P. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol [in press].
52. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, and Sandstede J Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy Am J Cardiol 97 2006 1515 1518
53. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, and Quezado M Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement Virchows Arch 448 2005 1 7
54. Keslova-Veselikova J, Hulkova H, Dobrovolny R, Asfaw B, Poupetova H, Berna L, Sikora J, Golan L, Ledvinova J, and Elleder M Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients Virchows Arch 452 2008 651 665
55. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, and Strotmann J Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy. Evidence for a better outcome with early treatment Circulation 119 2009 524 529
56. Hughes DA Early therapeutic intervention in females with Fabry disease? Acta Paediatr Suppl 97 2008 41 47
57. Ramaswami U Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa Acta Paediatr Suppl 97 2008 38 40
58. Pintos-Morell G, and Beck M Fabry disease in children and the effects of enzyme replacement treatment Eur J Pediat 2009 [Epub]
59. Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Odaka H, and Owada M Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes Pediatr Nephrol 23 2008 1461 1471